Pharmacovirological Impact of an Integrase Inhibitor on Human Immunodeficiency Virus Type 1 cDNA Species In Vivo

Clinical trials of the first approved integrase inhibitor (INI), raltegravir, have demonstrated a drop in the human immunodeficiency virus type 1 (HIV-1) RNA loads of infected patients that was unexpectedly more rapid than that with a potent reverse transcriptase inhibitor, and apparently dose indep...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Goffinet, Christine, Allespach, Ina, Oberbremer, Lena, Golden, Pamela L., Foster, Scott A., Johns, Brian A., Weatherhead, Jason G., Novick, Steven J., Chiswell, Karen E., Garvey, Edward P., Keppler, Oliver T.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society for Microbiology (ASM) 2009
Предметы:
Vaccines and Antiviral Agents
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC2708607/
https://ncbi.nlm.nih.gov/pubmed/19458008
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.00683-09
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы